{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:02:07Z","timestamp":1792695727249,"version":"4.5.0"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2028235"],"award-info":[{"award-number":["2028235"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021954","name":"Tour de Cure Ltd","doi-asserted-by":"publisher","award":["RSP-433-2024"],"award-info":[{"award-number":["RSP-433-2024"]}],"id":[{"id":"10.13039\/501100021954","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.neo.2025.101231","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T03:52:49Z","timestamp":1758599569000},"page":"101231","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["PDGFRA in paediatric high-grade glioma \u2013 target or distraction?"],"prefix":"10.1016","volume":"69","author":[{"given":"Natalie","family":"Le","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2976-8617","authenticated-orcid":false,"given":"Paul G.","family":"Ekert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4322-8203","authenticated-orcid":false,"given":"Lauren M.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2914-8637","authenticated-orcid":false,"given":"Neevika","family":"Manoharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neo.2025.101231_bib0001","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noac161","article-title":"CBTRUS statistical Report: pediatric Brain tumor Foundation childhood and adolescent primary brain and other Central nervous system tumors diagnosed in the United States in 2014-2018","volume":"24","author":"Ostrom","year":"2022","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.neo.2025.101231_bib0002","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1200\/JCO.2009.26.7252","article-title":"Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease","volume":"28","author":"Paugh","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neo.2025.101231_bib0003","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/s41591-024-02863-5","article-title":"Functional precision medicine for pediatric cancers","volume":"30","author":"Dolman","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.neo.2025.101231_bib0004","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/ppe.12895","article-title":"Childhood cancer survival and avoided deaths in Australia, 1983-2016","volume":"37","author":"Youlden","year":"2023","journal-title":"Paediatr. Perinat. Epidemiol."},{"key":"10.1016\/j.neo.2025.101231_bib0005","doi-asserted-by":"crossref","first-page":"390","DOI":"10.21873\/cgp.20328","article-title":"Molecular genetics and targeted therapies for paediatric high-grade glioma","volume":"19","author":"Rallis","year":"2022","journal-title":"Cancer Genom. Proteom."},{"key":"10.1016\/j.neo.2025.101231_bib0006","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1038\/s41388-021-01841-2","article-title":"Receptor tyrosine kinases and cancer: oncogenic mechanisms and therapeutic approaches","volume":"40","author":"Saraon","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.neo.2025.101231_bib0007","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1038\/ng.2762","article-title":"Emerging landscape of oncogenic signatures across human cancers","volume":"45","author":"Ciriello","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neo.2025.101231_bib0008","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s41467-021-21081-y","article-title":"A. pediatric brain tumor atlas of genes deregulated by somatic genomic rearrangement","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neo.2025.101231_bib0009","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202114608","article-title":"In vitro and in\u2009vivo drug screens of tumor cells identify novel therapies for high-risk child cancer","volume":"14","author":"Lau","year":"2022","journal-title":"EMBo Mol. Med."},{"key":"10.1016\/j.neo.2025.101231_bib0010","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.neo.2025.101231_bib0011","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ccell.2017.08.017","article-title":"Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma","volume":"32","author":"Mackay","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.neo.2025.101231_bib0012","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/ng.2925","article-title":"Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma","volume":"46","author":"Taylor","year":"2014","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neo.2025.101231_bib0013","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature10833","article-title":"Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma","volume":"482","author":"Schwartzentruber","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.neo.2025.101231_bib0014","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/ng.2938","article-title":"The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma","volume":"46","author":"Wu","year":"2014","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neo.2025.101231_bib0015","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The somatic genomic landscape of glioblastoma","volume":"155","author":"Brennan","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.neo.2025.101231_bib0016","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/nature07385","article-title":"Comprehensive genomic characterization defines human glioblastoma genes and core pathways","volume":"455","author":"McLendon","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.neo.2025.101231_bib0017","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1158\/2159-8290.CD-19-1030","article-title":"Infant high-grade gliomas comprise multiple subgroups characterized by novel targetable gene fusions and favorable outcomes","volume":"10","author":"Clarke","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.neo.2025.101231_bib0018","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s00401-020-02155-5","article-title":"Pediatric bithalamic gliomas have a distinct epigenetic signature and frequent EGFR exon 20 insertions resulting in potential sensitivity to targeted kinase inhibition","volume":"139","author":"Mondal","year":"2020","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neo.2025.101231_bib0019","doi-asserted-by":"crossref","first-page":"65696","DOI":"10.18632\/oncotarget.11602","article-title":"Characterizing and targeting PDGFRA alterations in pediatric high-grade glioma","volume":"7","author":"Koschmann","year":"2016","journal-title":"Oncotarget."},{"key":"10.1016\/j.neo.2025.101231_bib0020","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.ccell.2025.02.018","article-title":"Effective targeting of PDGFRA-altered high-grade glioma with avapritinib","volume":"43","author":"Mayr","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.neo.2025.101231_bib0021","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.26551","article-title":"Extent of tumor resection and survival in pediatric patients with high-grade gliomas: a systematic review and meta-analysis","volume":"5","author":"Hatoum","year":"2022","journal-title":"JAMa Netw. Open."},{"key":"10.1016\/j.neo.2025.101231_bib0022","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/neuonc\/noq191","article-title":"Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group","volume":"13","author":"Cohen","year":"2011","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.neo.2025.101231_bib0023","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.662209","article-title":"Radiosensitization in pediatric high-grade glioma: targets, resistance and developments","volume":"11","author":"Metselaar","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.neo.2025.101231_bib0024","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK-fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neo.2025.101231_bib0025","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1093\/neuonc\/noac087","article-title":"Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)","volume":"24","author":"Desai","year":"2022","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.neo.2025.101231_bib0026","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1056\/NEJMc2101264","article-title":"Lorlatinib in a child with ALK-fusion\u2013Positive high-grade glioma","volume":"385","author":"Bagchi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neo.2025.101231_bib0027","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3389\/fonc.2014.00067","article-title":"Phase II trial of Erlotinib during and after radiotherapy in children with newly diagnosed high-grade gliomas","volume":"4","author":"Qaddoumi","year":"2014","journal-title":"Front. Oncol."},{"key":"10.1016\/j.neo.2025.101231_bib0028","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/neuonc\/noq141","article-title":"Innovative therapies for children with cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing\/refractory brain tumors","volume":"13","author":"Geoerger","year":"2011","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.neo.2025.101231_bib0029","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/neuonc\/noq199","article-title":"A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the Pediatric Brain Tumor Consortium","volume":"13","author":"Pollack","year":"2011","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.neo.2025.101231_bib0030","first-page":"1786","article-title":"E.pidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of Childhood1","volume":"5","author":"Bredel","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.neo.2025.101231_bib0031","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1159\/000088731","article-title":"E.xpression of p53, EGFR, pRb and bcl-2 proteins in pediatric glioblastoma multiforme: a study of 54 patients","volume":"41","author":"Ganigi","year":"2005","journal-title":"Pediatr. Neurosurg."},{"key":"10.1016\/j.neo.2025.101231_bib0032","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s11060-013-1316-y","article-title":"Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry","volume":"116","author":"Gallego","year":"2014","journal-title":"J. Neuro. Oncol."},{"key":"10.1016\/j.neo.2025.101231_bib0033","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11060-009-0067-2","article-title":"Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme","volume":"98","author":"Peereboom","year":"2010","journal-title":"J. Neuro.-Oncol."},{"key":"10.1016\/j.neo.2025.101231_bib0034","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1016\/j.bbapap.2012.10.015","article-title":"Platelet-derived growth factors and their receptors: structural and functional perspectives","volume":"1834","author":"Chen","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.neo.2025.101231_bib0035","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/joim.12690","article-title":"Involvement of platelet-derived growth factor ligands and receptors in tumorigenesis","volume":"283","author":"Heldin","year":"2018","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.neo.2025.101231_bib0036","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.bbrc.2019.01.029","article-title":"Platelet-derived growth factor receptor \u03b1 gene is regulated by multiple first exons","volume":"510","author":"Minato","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neo.2025.101231_bib0037","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.cell.2011.06.014","article-title":"Mosaic analysis with double markers reveals tumor cell of origin in glioma","volume":"146","author":"Liu","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.neo.2025.101231_bib0038","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1523\/JNEUROSCI.17-01-00125.1997","article-title":"Developmental expression of platelet-derived growth factor \u03b1-receptor in neurons and glial cells of the mouse CNS","volume":"17","author":"Oumesmar","year":"1997","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neo.2025.101231_bib0039","doi-asserted-by":"crossref","first-page":"6219","DOI":"10.1158\/0008-5472.CAN-13-1491","article-title":"Novel oncogenic PDGFRA mutations in pediatric high-grade gliomas","volume":"73","author":"Paugh","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.neo.2025.101231_bib0040","doi-asserted-by":"crossref","first-page":"4583","DOI":"10.1038\/s41467-018-06949-w","article-title":"Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies","volume":"9","author":"Ip","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neo.2025.101231_bib0041","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1038\/onc.2013.218","article-title":"PDGFRA alterations in cancer: characterization of a gain-of-function V536E transmembrane mutant as well as loss-of-function and passenger mutations","volume":"33","author":"Velghe","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.neo.2025.101231_bib0042","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.bbrc.2016.06.117","article-title":"Structural and biochemical studies of the PDGFRA kinase domain","volume":"477","author":"Liang","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neo.2025.101231_bib0043","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12964-015-0096-8","article-title":"Constitutive activation of oncogenic pdgfr\u03b1-mutant proteins occurring in GIST patients induces receptor mislocalisation and alters pdgfr\u03b1 signalling characteristics","volume":"13","author":"Bahlawane","year":"2015","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.neo.2025.101231_bib0044","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.critrevonc.2016.11.008","article-title":"Platelet-derived growth factor receptors (PDGFRs) fusion genes involvement in hematological malignancies","volume":"109","author":"Appiah-Kubi","year":"2017","journal-title":"Crit. Rev. Oncol\/Hematol."},{"key":"10.1016\/j.neo.2025.101231_bib0045","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.neo.2025.101231_bib0046","doi-asserted-by":"crossref","first-page":"7600","DOI":"10.1038\/s41467-023-43373-1","article-title":"Genomic profiling of subcutaneous patient-derived xenografts reveals immune constraints on tumor evolution in childhood solid cancer","volume":"14","author":"He","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neo.2025.101231_bib0047","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s00401-018-1845-8","article-title":"Genomic analysis reveals secondary glioblastoma after radiotherapy in a subset of recurrent medulloblastomas","volume":"135","author":"Phi","year":"2018","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neo.2025.101231_bib0048","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1101\/gad.1972310","article-title":"PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas","volume":"24","author":"Ozawa","year":"2010","journal-title":"Genes Dev."},{"key":"10.1016\/j.neo.2025.101231_bib0049","doi-asserted-by":"crossref","first-page":"889","DOI":"10.15252\/msb.20166969","article-title":"Single-cell sequencing maps gene expression to mutational phylogenies in PDGF- and EGF-driven gliomas","volume":"12","author":"M\u00fcller","year":"2016","journal-title":"Mol. Syst. Biol."},{"key":"10.1016\/j.neo.2025.101231_bib0050","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1038\/s41591-024-03044-0","article-title":"Precision-guided treatment in high-risk pediatric cancers","volume":"30","author":"Lau","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.neo.2025.101231_bib0051","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/2051-5960-2-23","article-title":"The prognostic role of intragenic copy number breakpoints and identification of novel fusion genes in paediatric high grade glioma","volume":"2","author":"Carvalho","year":"2014","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.neo.2025.101231_bib0052","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/sj.onc.1206160","article-title":"A. human brain tumor-derived PDGFR-\u03b1 deletion mutant is transforming","volume":"22","author":"Clarke","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.neo.2025.101231_bib0053","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12943-018-0782-4","article-title":"M.echanisms of receptor tyrosine kinase activation in cancer","volume":"17","author":"Du","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.neo.2025.101231_bib0054","doi-asserted-by":"crossref","first-page":"e2332","DOI":"10.1002\/brb3.2332","article-title":"P.renatal overexpression of platelet-derived growth factor receptor A results in central nervous system hypomyelination","volume":"11","author":"Cardona","year":"2021","journal-title":"Brain Behav."},{"key":"10.1016\/j.neo.2025.101231_bib0055","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.ccell.2017.09.014","article-title":"H3.3K27M cooperates with Trp53 loss and PDGFRA gain in mouse embryonic neural progenitor cells to induce invasive high-grade gliomas","volume":"32","author":"Pathania","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.neo.2025.101231_bib0056","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s12017-023-08749-y","article-title":"PDGFRA, KIT, and KDR gene amplification in glioblastoma: heterogeneity and clinical significance","volume":"25","author":"Carlotto","year":"2023","journal-title":"Neuromolecular. Med."},{"key":"10.1016\/j.neo.2025.101231_bib0057","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0071777","article-title":"Distinct phenotypic differences associated with differential amplification of receptor tyrosine kinase genes at 4q12 in glioblastoma","volume":"8","author":"Burford","year":"2013","journal-title":"PLoS. One"},{"key":"10.1016\/j.neo.2025.101231_bib0058","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/sj.bjc.6605225","article-title":"Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas","volume":"101","author":"Martinho","year":"2009","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.neo.2025.101231_bib0059","doi-asserted-by":"crossref","first-page":"18494","DOI":"10.1074\/jbc.REV120.015190","article-title":"Ligand bias in receptor tyrosine kinase signaling","volume":"295","author":"Karl","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neo.2025.101231_bib0060","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1101\/gad.903001","article-title":"PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo","volume":"15","author":"Dai","year":"2001","journal-title":"Genes Dev."},{"key":"10.1016\/j.neo.2025.101231_bib0061","doi-asserted-by":"crossref","DOI":"10.1593\/neo.08814","article-title":"Tumor progression and oncogene addiction in a PDGF-B-induced model of gliomagenesis","volume":"10","author":"Calzolari","year":"2008","journal-title":"Neoplasia"},{"key":"10.1016\/j.neo.2025.101231_bib0062","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1158\/1541-7786.MCR-16-0389","article-title":"Histone H3.3K27M represses p16 to accelerate gliomagenesis in a Murine model of DIPG","volume":"15","author":"Cordero","year":"2017","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.neo.2025.101231_bib0063","first-page":"3213","article-title":"Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops","volume":"52","author":"Hermanson","year":"1992","journal-title":"Cancer Res."},{"key":"10.1016\/j.neo.2025.101231_bib0064","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27035","article-title":"Phase 1 trial, pharmacokinetics, and pharmacodynamics of dasatinib combined with crizotinib in children with recurrent or progressive high-grade and diffuse intrinsic pontine glioma","volume":"65","author":"Broniscer","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.neo.2025.101231_bib0065","doi-asserted-by":"crossref","first-page":"5313","DOI":"10.1172\/JCI133310","article-title":"Everolimus improves the efficacy of dasatinib in pdgfr\u03b1-driven glioma","volume":"130","author":"Miklja","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.neo.2025.101231_bib0066","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1158\/1078-0432.CCR-13-0306","article-title":"Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma","volume":"19","author":"Broniscer","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.neo.2025.101231_bib0067","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1215\/15228517-2006-031","article-title":"Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report","volume":"9","author":"Pollack","year":"2007","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.neo.2025.101231_bib0068","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1016\/j.ejca.2009.05.008","article-title":"A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours","volume":"45","author":"Baruchel","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.neo.2025.101231_bib0069","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1002\/cam4.713","article-title":"Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children's oncology group study ACNS1021","volume":"5","author":"Wetmore","year":"2016","journal-title":"Cancer Med."},{"key":"10.1016\/j.neo.2025.101231_bib0070","first-page":"vdab179","article-title":"Phase I study using crenolanib to target PDGFR kinase in children and young adults with newly diagnosed DIPG or recurrent high-grade glioma, including DIPG","volume":"3","author":"Tinkle","year":"2021","journal-title":"Neurooncol. Adv."},{"key":"10.1016\/j.neo.2025.101231_bib0071","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1016\/j.ejca.2009.03.007","article-title":"Target-driven exploratory study of imatinib mesylate in children with solid malignancies by the Innovative Therapies for Children with Cancer (ITCC) European Consortium","volume":"45","author":"Geoerger","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.neo.2025.101231_bib0072","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1093\/neuonc\/nov011","article-title":"Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627)","volume":"17","author":"Lassman","year":"2015","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.neo.2025.101231_bib0073","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S1470-2045(20)30269-2","article-title":"Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial","volume":"21","author":"Heinrich","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.neo.2025.101231_bib0074","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/s41591-021-01538-9","article-title":"Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 explorer trial","volume":"27","author":"DeAngelo","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.neo.2025.101231_bib0075","doi-asserted-by":"crossref","first-page":"e694","DOI":"10.1002\/mco2.694","article-title":"Mechanisms of resistance to tyrosine kinase inhibitor-targeted therapy and overcoming strategies","volume":"5","author":"Ou","year":"2024","journal-title":"MedComm"},{"key":"10.1016\/j.neo.2025.101231_bib0076","doi-asserted-by":"crossref","first-page":"546","DOI":"10.4143\/crt.2015.015","article-title":"Efficacy of Imatinib in patients with platelet-derived growth factor receptor alpha\u2013Mutated gastrointestinal stromal tumors","volume":"48","author":"Yoo","year":"2016","journal-title":"Cancer Res. Treat."},{"key":"10.1016\/j.neo.2025.101231_bib0077","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1158\/2159-8290.CD-14-0763","article-title":"FGFR-mediated reactivation of MAPK signaling attenuates antitumor effects of Imatinib in gastrointestinal stromal tumors","volume":"5","author":"Li","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.neo.2025.101231_bib0078","doi-asserted-by":"crossref","first-page":"eaao1690","DOI":"10.1126\/scitranslmed.aao1690","article-title":"A precision therapy against cancers driven by KIT\/PDGFRA mutations","volume":"9","author":"Evans","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.neo.2025.101231_bib0079","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1158\/2159-8290.CD-20-0487","article-title":"Resistance to Avapritinib in PDGFRA-driven GIST is caused by secondary mutations in the PDGFRA kinase domain","volume":"11","author":"Grunewald","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.neo.2025.101231_bib0080","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41467-023-44376-8","article-title":"Avapritinib-based SAR studies unveil a binding pocket in KIT and PDGFRA","volume":"15","author":"Teuber","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neo.2025.101231_bib0081","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/s41588-020-0678-2","article-title":"Extrachromosomal DNA is associated with oncogene amplification and poor outcome across multiple cancers","volume":"52","author":"Kim","year":"2020","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neo.2025.101231_bib0082","doi-asserted-by":"crossref","first-page":"8468","DOI":"10.1038\/srep08468","article-title":"Double minute amplification of mutant PDGF receptor \u03b1 in a mouse glioma model","volume":"5","author":"Zou","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neo.2025.101231_bib0083","doi-asserted-by":"crossref","first-page":"5690","DOI":"10.1038\/ncomms6690","article-title":"Extrachromosomal driver mutations in glioblastoma and low-grade glioma","volume":"5","author":"Nikolaev","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neo.2025.101231_bib0084","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1126\/science.1241328","article-title":"Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA","volume":"343","author":"Nathanson","year":"2014","journal-title":"Science"}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558625001113?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558625001113?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T13:20:59Z","timestamp":1772889659000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558625001113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":84,"alternative-id":["S1476558625001113"],"URL":"https:\/\/doi.org\/10.1016\/j.neo.2025.101231","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PDGFRA in paediatric high-grade glioma \u2013 target or distraction?","name":"articletitle","label":"Article Title"},{"value":"Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neo.2025.101231","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. CCBYLICENSE","name":"copyright","label":"Copyright"}],"article-number":"101231"}}